Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach

Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach

Background: Outbreak of COVID-19 has been recognized as a global health concern since it causes high rates of morbidity and mortality. No specific antiviral drugs are available for the treatment of COVID-19 till date. Drug repurposing strategy helps to find out the drugs for COVID-19 treatment from...

Full description

Bibliographic Details
Main Authors: Purushothaman Indu, Marimuthu Ragavan Rameshkumar, Narasingam Arunagirinathan, Naif Abdullah Al-Dhabi, Mariadhas Valan Arasu, Savarimuthu Ignacimuthu
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Journal of Infection and Public Health
Subjects:
COVID-19
SARS-CoV-2
Main protease
RNA-dependent RNA polymerase
Antiviral drugs
Docking
Online Access:http://www.sciencedirect.com/science/article/pii/S1876034120307127

Internet

http://www.sciencedirect.com/science/article/pii/S1876034120307127

Similar Items